Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25428430 | 0.82 | TRPV1 (0.36) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL30544022 | 0.82 | TRPV1 (0.36) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL25341570 | 0.82 | CCNB2 (0.36) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL25428722 | 0.79 | TRPV1 (0.35) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL30544083 | 0.79 | TRPV1 (0.35) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL25973975 | 0.79 | KIF11 (0.36) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL25951852 | 0.78 | TRPV1 (0.41) | TRPA1 | |
| SCHEMBL25973977 | 0.75 | TRPV1 (0.39) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL25379344 | 0.75 | ALOX5AP (0.38) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL26203422 | 0.71 | MAPT (0.35) | CCNB2CDK1CCNB1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |